Humoral immune response to allograft valve tissue pretreated with an antigen reduction process.
The humoral immune response to allograft heart valves as measured by PRA was absent in 52 of 57 (91%) patients at 1 month and was absent in 43 of 49 (88%) at 3 months in allograft valves treated with the SynerGraft process for antigen reduction. Short-term valve function is satisfactory. This may be associated with improved durability and long-term function.
Elkins
R C
RC
Section of Thoracic and Cardiovascular Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA.
Lane
M M
MM
Capps
S B
SB
McCue
C
C
Dawson
P E
PE
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000917:Antibody Formation / Q000276:immunology; D001021:Aortic Valve / Q000000981:diagnostic imaging / Q000276:immunology* / Q000637:transplantation; D001323:Autoantibodies / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D015925:Cryopreservation; D005260:Female; D006082:Graft Enhancement, Immunologic; D006349:Heart Valve Diseases / Q000601:surgery; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011664:Pulmonary Valve / Q000000981:diagnostic imaging / Q000276:immunology* / Q000637:transplantation; D014184:Transplantation, Homologous / Q000276:immunology*; D014463:Ultrasonography
D001323:Autoantibodies; D015395:Histocompatibility Antigens Class I